Clinical Trial

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Study acronym: ROCKET-ASCEND
Terminated Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Protocol Amendment History 2 changes
critical Trial terminated 2026-07-17
critical Reason stopped changed: — → Sponsor Decision 2026-07-17
Trial Details
NCT Number NCT05882877
Lead Sponsor Amgen
Conditions Atopic Dermatitis
Enrollment 2,621 participants
Start Date 2023-05-31
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-16